MC
NAMS icon

Maverick Capital’s NewAmsterdam Pharma NAMS Stock Holding History

Maverick Capital’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$70M Buy
2,186,402
+292,176
+15% +$9.52M 0.81% 39
2025
Q4 		$66.4M Buy
1,894,226
+389,479
+26% +$14.2M 0.71% 37
2025
Q3 		$42.8M Sell
1,504,747
-27,127
-2% -$650K 0.57% 44
2025
Q2 		$27.7M Buy
1,531,874
+982,405
+179% +$17.9M 0.42% 47
2025
Q1 		$11.2M Buy
549,469
+199,464
+57% +$4.43M 0.2% 57
2024
Q4 		$9M Buy
+350,005
New +$7.43M 0.16% 53

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Maverick Capital's NAMS Position: Q1 2026 in Review

Maverick Capital increased its NewAmsterdam Pharma (NAMS) stake by 15% in Q1 2026, buying an estimated $9.52M and bringing the position to 2,186,402 shares worth $70M. The position accounts for 0.81% of the portfolio, ranked #39.

Maverick Capital first reported a position in NAMS in Q4 2024 and has held it in 6 quarters since. 170 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

  • Maverick Capital held 2,186,402 shares of NewAmsterdam Pharma worth $70M as of Q1 2026.
  • Maverick Capital bought 292,176 NewAmsterdam Pharma shares in Q1 2026, an estimated $9.52M.
  • NewAmsterdam Pharma made up 0.81% of Maverick Capital's portfolio in Q1 2026, its #39 holding.
  • Maverick Capital first reported a position in NewAmsterdam Pharma in Q4 2024 and has held it in 6 quarters since.
  • 170 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Maverick Capital's 13F filing for Q1 2026, filed 15 May 2026.